Hikma Pharmaceuticals Regulatory News (HIK)

12 May 2008 14:37

Annual Information Update

LONDON, 12 May 2008. In accordance with Prospectus Rule 5.2, Hikma Pharmaceuticals PLC ("Hikma" or "the Company") (LSE: HIK and DFX:HIK) sets out below a summary of the information which has been published or made available to the public over the previous 12 months. The information referred to in this Update was up to date at the time the information was published, but some information may now be out of date.

Stock Exchange announcements

Announcements made by the Company via RNS, a Regulatory Information Service, may be viewed and downloaded from the London Stock Exchange website (www.londonstockexchange.com/marketnews) or from the press releases page on the Company's website at (http://investors.hikma.com/hikma/regulatorynews.jsp). The Stock Exchange announcements made during the defined period are:

Any related documents are available at the UKLA's Document Viewing Facility, Financial Services Authority, 25 the North Colonnade, London, E14 5HS. 

All of the above announcements were also made by the Company via the Dubai International Financial Exchange ("DIFX") CANDI system. These announcements may be viewed and downloaded from the DIFX website (www.difx.ae).

Documents filed with Companies House

The Company submitted filings to Companies House, in relation to the Company's annual return, financial report & accounts, appointments and resignations of directors, allotments of shares and ordinary and special resolutions passed at the Company's 2007 Annual General Meeting. Copies of all these documents can be found on the Companies House website at www.companieshouse.gov.uk or through Companies House Direct at www.direct.companieshouse.gov.uk.

Henry Knowles Company Secretary12 May 2008

- ENDS -

Enquiries:

Notes to Editors

About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed pharmaceutical products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics". Hikma's operations are based principally in the Middle East and North Africa ("MENA") region, where it is a market leader and sells across 17 countries, the United States and Europe. In 2007, the Group achieved revenues of $449 million (2006 $317 million) and profit attributable to shareholders was $63 million (2006 $55 million). For news and other information, please visit www.hikma.com.